2600 Hilltop Drive
Building B, 3rd Floor
About DiaCarta Inc.
DiaCarta is a translational genomics and personalized diagnostics company based in Richmond, California. We are dedicated to the science of rapid, highly sensitive detection technologies and diagnostic solutions for healthcare that positively impact treatment plans and improve the well being of individuals around the world.
CEO: Aiguo Zhang
CSO: Michael J. Powell
Tweets by DiaCarta
8 articles with DiaCarta Inc.
The tests are validated on standard real-time qPCR instruments including Thermo Fisher Scientific Quantstudio 5, Roche LightCycler® 480 and Bio-Rad CFX384.
DiaCarta, Inc., Awarded $2 Million NCI Contract to Pursue Regulatory Approval of Innovative Cancer Radiation Response Blood Test
DIACARTA, Inc. announced today that it has received a $2 million National Cancer Institute (NCI) Small Business Innovation Research (SBIR) contract to continue development of its RadToxTM cfDNA radiation therapy toxicity monitoring test kit for cancer patients.
DiaCarta has been recognized as one of the Top 10 In-Vitro Diagnostic Technology Solution Providers 2018 by Med Tech Outlook Magazine.
DiaCarta Inc. today announced that it has signed a distribution agreement with Arrow Diagnostics.
CIO Applications has chosen DiaCarta as one of the Top 25 Life Sciences Technology Vendors 2018.
DiaCarta and MIODx Join Forces to Develop a Diagnostic Test to Predict Patient Responses to Immunotherapy
The test is based on MIODx’s ClonoMap™ immune sequencing platform, and is designed to predict patient response to immunotherapy.
2/13/2018The second closing was led by Fortune Fountain Capital and was also subscribed to by Good Health Capita.